Cosmos Health Appoints AI-Drug Discovery Leader from Athos Therapeutics
Cosmos Health appointed Dr. Dimitrios Iliopoulos to its Advisory Board to lead AI-driven drug discovery and clinical-stage biotech development. Dr. Iliopoulos co-founded Athos Therapeutics, whose AthosOmics.AI platform discovered ATH-063 now in Phase 2 ulcerative colitis trials, and he has authored 130+ papers with over 24,000 citations.
1. Advisory Board Appointment
Cosmos Health named Dr. Dimitrios Iliopoulos to its Advisory Board effective February 24, 2026. He will focus on supporting the company’s biotechnology initiatives with an emphasis on AI-driven drug discovery and clinical-stage therapeutic development.
2. Professional Background
Dr. Iliopoulos is co-founder and CEO of Athos Therapeutics, where his AthosOmics.AI platform led to the discovery of ATH-063 now in Phase 2 ulcerative colitis trials. He began at Harvard Medical School, later became a tenured professor at UCLA, has published 130+ peer-reviewed articles with 24,000+ citations, and is listed among the top 2% of scientists globally.
3. Strategic Implications
The appointment strengthens Cosmos Health’s R&D capabilities in autoimmune and oncology areas, enhancing its vertically integrated platform. His expertise in AI-enabled drug development aligns with the company’s strategy to expand clinical-stage research and build meaningful commercial therapies worldwide.